Paul A Cornelius

Title: Paul A. Cornelius: Innovator in Photolysis Technology

Introduction

Paul A. Cornelius is a notable inventor based in Philadelphia, PA (US). He has made significant contributions to the field of biological treatment processes. His innovative work focuses on the selective photolysis of nucleic acids, which has important implications for medical applications.

Latest Patents

Paul A. Cornelius holds a patent for a "Pulsed light selective photolysis process for treatment of biological." This novel irradiation process is designed to treat biological media such as blood fractions, genetically engineered protein products, and vaccine preparations. The process photolyzes nucleic acids preferentially over proteins, effectively inactivating DNA- or RNA-containing pathogens while preserving the functionality of proteins. The method involves irradiating the medium with pulsed light at specific wavelengths and fluxes, allowing nucleic acids to absorb radiation and undergo photolysis, while proteins remain largely intact.

Career Highlights

Cornelius is associated with Kollmorgen Corporation, where he applies his expertise in photolysis technology. His work has the potential to revolutionize treatments in various biological applications, enhancing the safety and efficacy of medical products.

Collaborations

Some of his notable coworkers include Harvey Rubin and Robin M. Hochstrasser. Their collaborative efforts contribute to advancing the field of biological treatments and photolysis processes.

Conclusion

Paul A. Cornelius is a pioneering inventor whose work in pulsed light selective photolysis represents a significant advancement in the treatment of biological media. His innovative approach has the potential to improve medical treatments and enhance the safety of biological products.